Tyra Biosciences, Inc. TYRA Facilities And Other Costs — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tyra Biosciences, Inc.'s facilities and other costs — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tyra Biosciences, Inc.'s facilities and other costs — research and development expense?
- Tyra Biosciences, Inc. (TYRA) reported facilities and other costs — research and development expense of $1.63M in Q1 2026.
- How has Tyra Biosciences, Inc.'s facilities and other costs — research and development expense changed year-over-year?
- Tyra Biosciences, Inc.'s facilities and other costs — research and development expense increased by 16.3% year-over-year, from $1.41M to $1.63M.
- What is the long-term trend for Tyra Biosciences, Inc.'s facilities and other costs — research and development expense?
- Over 2 years (2023 to 2025), Tyra Biosciences, Inc.'s facilities and other costs — research and development expense has grown at a 19.8% compound annual growth rate (CAGR), from $4.25M to $6.1M.
- What does facilities and other costs — research and development expense mean?
- This metric represents the portion of research and development expenditures specifically allocated to the facilities and infrastructure segment of the company's operations. It captures the overhead and operational costs required to maintain the specialized laboratory environments and technical resources necessary for drug discovery and clinical development programs. Tracking this expense helps investors understand the fixed cost burden associated with supporting the company's internal precision medicine platform and ongoing clinical trials.